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Reduction in Central H2O2 Levels Prevents Voluntary
Ethanol Intake in Mice: A Role for the Brain Catalase-
H2O2 System in Alcohol Binge Drinking
Juan Carlos Ledesma, Pablo Balin˜o, and Carlos M. G. Aragon
Background: Hydrogen peroxide (H2O2) is the cosubstrate used by the enzyme catalase to form
Compound I (the catalase-H2O2 system), which is the major pathway for the conversion of ethanol
(EtOH) into acetaldehyde in the brain. This centrally formed acetaldehyde has been shown to be
involved in some of the psychopharmacological effects induced by EtOH in rodents, including volun-
tary alcohol intake. It has been observed that different levels of this enzyme in the central nervous sys-
tem (CNS) result in variations in the amount of EtOH consumed. This has been interpreted to mean
that the brain catalase-H2O2 system, by determining EtOH metabolism, mediates alcohol self-adminis-
tration. To date, however, the role of H2O2 in voluntary EtOH drinking has not been investigated.
Methods: In the present study, we explored the consequence of a reduction in cerebral H2O2 levels in
volitional EtOH ingestion. With this end in mind, we injected mice of the C57BL/6J strain intraperito-
neally with the H2O2 scavengers alpha-lipoic acid (LA; 0 to 50 mg/kg) or ebselen (Ebs; 0 to 25 mg/kg)
15 or 60 minutes, respectively, prior to offering them an EtOH (10%) solution following a drinking-
in-the-dark procedure. The same procedure was followed to assess the selectivity of these compounds in
altering EtOH intake by presenting mice with a (0.1%) solution of saccharin. In addition, we indirectly
tested the ability of LA and Ebs to reduce brain H2O2 availability.
Results: The results showed that both LA and Ebs dose-dependently reduced voluntary EtOH
intake, without altering saccharin consumption. Moreover, we demonstrated that these treatments
decreased the central H2O2 levels available to catalase.
Conclusions: Therefore, we propose that the amount of H2O2 present in the CNS, by determining
brain acetaldehyde formation by the catalase-H2O2 system, could be a factor that determines an ani-
mal’s propensity to consume EtOH.
Key Words: Ethanol Intake, Alpha-Lipoic Acid, Ebselen, H2O2, Catalase, Acetaldehyde.
HYDROGEN PEROXIDE (H2O2) is the cosubstrateused by catalase to form the catalase-H2O2 system
(known as Compound I), which is the major pathway of
brain ethanol (EtOH) metabolism (Zimatkin et al., 2006).
It has been postulated that central EtOH metabolism by
the activity of this enzymatic complex mediates some of
the psychopharmacological effects produced by this alcohol
(Deng and Deitrich, 2008). Previous research has demon-
strated that individual differences in the activity of brain
catalase in rats of the same strain correlate positively with
their voluntary EtOH intake (Amit and Aragon, 1988;
Aragon et al., 1985). Moreover, it has been shown that
strains of rats with higher brain catalase activity drink
more EtOH than other strains with a lower activity of this
enzyme in the central nervous system (CNS) (Gill et al.,
1996a). In another set of reports, it has been observed
that the administration of the brain catalase inhibitor
3-amino-1,2,4-triazole (AT) prevents voluntary EtOH
consumption in rats (Aragon and Amit, 1992; Tampier
et al., 1995). Existing data also showed that rats treated
with an anticatalase shRNA lentiviral vector, which inhib-
its catalase synthesis and expression in the CNS, consume
lower amounts of EtOH than their control mates (Karaha-
nian et al., 2011). Therefore, it has been proposed that
differences in brain catalase activity correlate positively
with the amount of EtOH intake and determine EtOH
consumption in rats.
On the other side, it has been reported that strains of mice
with a lower activity of this enzyme exhibited an increased
preference to voluntarily consume EtOH. Thus, acatalase-
mic mice, which have lower levels of catalase (50%) in the
brain, displayed a greater EtOH intake compared with nor-
mal mice (Aragon and Amit, 1993). Similarly, the C57BL/6J
strain of inbred mice, which have a significantly lower activ-
ity of this enzyme in the brain, showed an increment in the
amount of alcohol intake with regard to other strains with
higher levels of catalase, thus suggesting a negative correla-
tion between the expression of the enzyme catalase in the
CNS of mice and EtOH self-administration (Correa et al.,
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2004; Gill et al., 1996b). However, other studies showed that
mice treated with AT displayed a dose-dependent reduction
in their volitional EtOH intake (Koechling and Amit, 1994).
Overall, although the direction of the relationship between
catalase activity and EtOH ingestion is still not clear, given
all these data, it has been postulated that differences in brain
catalase may be one of the factors determining EtOH con-
sumption in alcohol na€ıve animals.
In addition to EtOH intake, there are many other behav-
iors that could be modulated by alterations or differences in
brain catalase. It has been shown that strains of mice with a
lower activity of this enzyme in the CNS exhibited a
decreased response to the locomotor-stimulating effects
induced by EtOH (Aragon and Amit, 1993; Correa et al.,
2004). Moreover, both rats and mice treated with the cata-
lase inhibitor AT or with the anticatalase shRNA lentiviral
vector displayed an attenuation of a wide range of EtOH-
elicited behaviors such as locomotor stimulation (Escaraba-
jal et al., 2000), conditioned place preference (Font et al.,
2008), and EtOH-induced reward and relapse (Quintanilla
et al., 2012) compared with their normal control mates.
These results indicate that this enzyme participates in the
mediation of some of the psychopharmacological effects
caused by alcohol.
Nonetheless, the exact contribution of the catalase-H2O2
system to EtOH-induced behaviors has yet to be investigated
in detail. In this respect, recent studies suggest that in addi-
tion to catalase, H2O2 could be a factor that modulates
EtOH behavioral effects. Interestingly, it has been demon-
strated that different treatments that boosted H2O2 central
levels produced an increase in EtOH-induced locomotor
stimulation in mice (Manrique et al., 2006; Pastor et al.,
2002). In contrast, administration of H2O2 scavengers, which
decrease H2O2 availability in the brain, reduced the locomo-
tor stimulation evoked by an EtOH challenge (Ledesma and
Aragon, 2012; Ledesma et al., 2012) and the acquisition and
reconditioning of EtOH-induced conditioned place prefer-
ence in mice (Ledesma and Aragon, 2013).
The aim of the present work was to evaluate the role of
H2O2 on EtOH binge drinking following a drinking-in-
the-dark (DID) procedure. Hence, we selected alpha-lipoic
acid (LA) and ebselen (Ebs) as H2O2 scavengers. These com-
pounds have been demonstrated to modulate brain H2O2
levels when administered systemically (Ledesma and Aragon,
2012, 2013; Ledesma et al., 2012). We hypothesized that the
reduction in endogenous H2O2 levels by LA and Ebs would
decrease the activity of the brain catalase-H2O2 system, and
therefore voluntary EtOH consumption. We have also
assessed whether these pharmacological tools were selective
in reducing EtOH intake when compared to a sweetened
solution. Moreover, the present investigation was also
extended to study the ability of these agents to reduce the
H2O2 levels in the brain. The results derived from the present
work highlight the relevance of central H2O2 availability and
thereby the functional role of catalase in volitional EtOH
intake.
MATERIALS ANDMETHODS
Subjects
Male mice of the C57BL/6J strain, obtained from Charles River
Laboratories (Madrid, Spain), were used. Animals were 5 weeks old
at the time of arrival and were housed inside the quarantine room
for 1 week under a 12-hour light/dark cycle (lights off at 6:00 AM).
Following this period, they were housed 1 per cage and acclimated
to the colony environment for at least 1 week before experiments
began. The temperature and humidity of the colony room were
maintained at 22 ! 1°C and 50 ! 5%, respectively. Food and
water were provided ad libitum throughout the study, except during
the restricted-access periods of EtOH drinking, in which water
was not available. All experimental procedures complied with the
European Community Council Directive (86/609/ECC) for the use
of laboratory animal subjects.
Drugs
LA (1,2-dithiolane-3-pentanoic acid), purchased from Sigma-
Aldrich Qu!ımica S.A. (Madrid, Spain), was dissolved in Dulbecco’s
phosphate-buffered saline (vehicle [Vh]) using a possible minimal
amount of 1 M NaOH solution. The final pH of the resulting solu-
tion was 7 ! 1. LA was injected intraperitoneally (IP) at doses of
12.5, 25, and 50 mg/kg. Ebs [2-phenyl-1,2 benzoisosenazol-3 (2H-
one)] (Sigma-Aldrich Qu!ımica S.A., Madrid, Spain) was dissolved
in Tween 80 at a concentration of 10% (Vh) and injected IP at doses
of 6.25, 12.5, and 25 mg/kg. Cyanamide (Sigma-Aldrich Qu!ımica
S.A.) was diluted in physiological saline (9% NaCl [Sal]) and
injected IP at a dose of 40 mg/kg. EtOH, obtained from Panreac
Qu!ımica S.A. (Madrid, Spain), was diluted in tap water from an ini-
tial stock of 96% EtOH, and presented in a glass cylinder at increas-
ing concentrations from 2 to 10% v/v. Saccharin 0.1% w/v (Sigma-
Aldrich Qu!ımica S.A.) was diluted in tap water. All the drug doses
and drinking solutions were selected based on previous reports
(Aragon and Amit, 1993; Font et al., 2006; Ledesma and Aragon,
2012; Ledesma et al., 2012; Sanchis-Segura et al., 1999).
General Behavioral Procedures
Voluntary EtOH Intake. Alcohol was always presented at the
beginning of the third hour of the animals’ dark cycle (at 9 AM).
Prior to the initiation of the experiments, mice were subjected to
a habituation period, for 10 days, in which exposure to EtOH
started with increasing concentrations of EtOH that changed
every 2 days by increments of 2% (from 2 to 10% w/v). This per-
iod of habituation to EtOH drinking has previously been used by
other authors, and serves to accustom animals to the smell and
flavor of EtOH. It also avoids the neophobia initially induced by
the presentation of new fluids in rodents (Aragon and Amit,
1993; Correa et al., 2004; Font et al., 2006). During EtOH pre-
sentation, the water bottles were always replaced with 10-
ml graduated glass cylinders containing an EtOH solution for
2 hours. When a concentration of EtOH of 10% was achieved,
the baseline phase started, which consists in presenting a 10% w/
v solution of EtOH every testing day until the intake of all mice
reached stable levels (for 1 week, data not shown). In this baseline
period, we followed the same schedule as in the experimental
phase, with the exception that no injections were given. The meth-
odology followed in the drinking procedures was a variation of
that described by Rhodes and colleagues (2005) and Kamdar and
colleagues (2007) known as drinking-in-the-dark (DID). Briefly,
the 2-day DID procedure was repeated in the same animals twice
a week (Monday-Tuesday, and Thursday-Friday, with Wednesday
off) for 2 weeks (weekend off). On the first day (Monday
and Thursday), all mice received Vh injections prior to EtOH
presentation, and on the second day (Tuesday and Friday) of
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each 2-day session, each mouse received an IP injection of one of
the drug doses at the same time interval as on the preceding day.
The order in which the drug doses were administered was coun-
terbalanced across animals and days. Although the DID test is
normally performed with 20% EtOH, in our experiments 10%
EtOH is used because it is the most widely used concentration in
pharmacological studies with EtOH (Aragon and Sternklar, 1985;
Correa et al., 2004; Kamdar et al., 2007; Koechling and Amit,
1994; Quintanilla et al., 2012).
Voluntary Saccharin Intake. As in the procedure described
above, the 2-day DID protocol was used to evaluate the effect of
our manipulations on voluntary saccharin intake. The same experi-
mental design was repeated with a new cohort of animals. Thus,
before the DID tests started, mice underwent a 1-week habituation
period to allow them to get accustomed to the flavor of saccharin
and the experimental conditions. The concentration of the saccharin
solution offered was always 0.1% w/v.
Experiment 1: Effect of Several Doses of LA on Voluntary EtOH
Intake. This experiment evaluated the effect of LA on voluntary
EtOH intake under the DID procedure outlined above. Thus, on
the test days, mice (n = 15) were injected with Vh or 1 of the LA
doses (12.5, 25, or 50 mg/kg) 15 minutes prior to EtOH (10%)
presentation. EtOH was available during 90 minutes, and
then the water bottles were replaced again until the next testing
session.
Experiment 2: Effect of LA on Voluntary Saccharin Intake. To
test the selectivity of LA in modifying voluntary EtOH (10%) con-
sumption, here the animals (n = 16) were offered a (0.1%) solution
of saccharin at the same time intervals as in Experiment 1. Thus,
mice were treated with Vh or LA (25 or 50 mg/kg) 15 minutes
before saccharin (0.1%) presentation.
Experiment 3: Effect of Several Doses of Ebs on Voluntary EtOH
Intake. The following experiment was identical to Experiment
1, with the exception that in this case, mice (n = 12) were treated
with Vh or Ebs (6.25, 12.5 or 25 mg/kg) 60 minutes before
placement of the EtOH (10%) cylinders. In addition, given that
previous reports showed that the effects of Ebs on EtOH-
induced behavior last longer than those of LA (Ledesma and
Aragon, 2012; Ledesma et al., 2012), in this study, to establish
the direct consequence of our treatments on alcohol intake
more thoroughly, the EtOH drinking solution was offered for
180 minutes.
Experiment 4: Effect of Ebs on Voluntary Saccharin Intake. Sim-
ilarly to Experiment 2, here, we evaluated the effect of Ebs on voli-
tional saccharin (0.1%) intake. For this purpose, animals (n = 14)
were injected with Vh or Ebs (12.5 or 25 mg/kg) 60 minutes prior to
offering them the (0.1%) saccharin solution for 180 minutes.
Experiments 5a and 5b: Determination of Brain Catalase Activ-
ity. The goal of this study was to examine whether LA and Ebs
were able to reduce central H2O2 levels available to catalase, and
therefore to test the putative mechanism of action by which these
pharmacological manipulations could interact with the metabolism
of EtOH in the brain. Through 2 separate experiments, we evalu-
ated the effect of these H2O2 scavengers on the inactivation of
brain catalase activity induced by cyanamide. The rationale for
this investigation was as follows: Cyanamide, like AT, is a non-
competitive catalase inhibitor that only inactivates catalase when
this enzyme reacts to H2O2 and forms Compound I (DeMaster
et al., 1986). That is, the effect of cyanamide on catalase is H2O2-
dependent (DeMaster et al., 1986). Therefore, the inactivation of
the brain catalase activity of mice treated with cyanamide could be
used as a measure of the amount of H2O2 produced in the brain
(Ledesma et al., 2012; Pastor et al., 2002). In other words, changes
in H2O2 levels could modify the inhibiting effect of cyanamide on
brain catalase activity. Thus, the inactivation of cerebral catalase
in animals treated with cyanamide may be used as an indirect indi-
cator of the formation of Compound I in the CNS. We hypothe-
sized here that the inhibition of brain catalase induced by
cyanamide will decrease in mice treated with the H2O2 sequestering
agents LA and Ebs (Bilska et al., 2007; Johnsen-Soriano et al.,
2007). To test this, EtOH-na€ıve animals (n = 6 per group) were
treated with Vh or LA (50 mg/kg; Experiment 5a) and with Vh or
Ebs (25 mg/kg; Experiment 5b); simultaneously, they were also
treated with Sal or cyanamide (40 mg/kg). Four hours after these
treatments, mice were perfused through the heart using 50 ml of a
heparinized (1,000 IU/l) isotonic saline solution. The whole brain
was removed and homogenized in phosphate buffer (50 mM; pH
7.0) with digitonin (0.01%). Brain homogenates were centrifuged
at 5,0009g for 15 minutes in an Eppendorf microcentrifuge.
Supernatant aliquots were used to determine brain catalase
levels. Catalase activity was assayed spectrophotometrically by
measuring the decrease in absorbance of H2O2 at 240 nm (є240 =
0.00394 mmol"1 9 mm"1). Protein levels were determined from
supernatants in accordance with the method described by Bradford
(1976).
Statistical Analyses
One- or 2-way analysis of variance (ANOVA), following post
hoc comparisons with Duncan’s post hoc test, was applied when
appropriate. The Statistica 6.1 (StatSoft, Tulsa, OK) software pack-
age was used.
RESULTS
Experiment 1: Effect of Several Doses of LA on Voluntary
EtOH Intake
Figure 1A shows the consequence of LA administration
(0, 12.5, 25, or 50 mg/kg) on EtOH (10%) consumption.
Results from a 1-way ANOVA indicated a significant effect
of the LA dose, F(3, 56) = 2.99, p < 0.05. Post hoc Duncan’s
comparisons revealed that animals drank less EtOH when
they were treated with the LA doses of 25 and 50 mg/kg
(p < 0.05).
Experiment 2: Effect of LA on Voluntary Saccharin Intake
As can be seen in Fig. 1B, LA (25 or 50 mg/kg) had no
effect on voluntary saccharin intake. This conclusion was
confirmed by a 1-way ANOVA, F(2, 45) = 0.77, p > 0.05.
Experiment 3: Effect of Several Doses of Ebs on Voluntary
EtOH Intake
Figure 2A represents the volitional EtOH (10%) ingestion
of mice previously treated with Ebs (0, 6.25, 12.5, and
25 mg/kg). The 1-way ANOVA showed a significant effect
for the Ebs dose, F(3, 44) = 13.66, p < 0.01. Duncan’s post
hoc test revealed that EtOH intake was statistically reduced
when animals were injected with the doses of Ebs of 12.5 and
25 mg/kg (p < 0.01).
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Experiment 4: Effect of Ebs on Voluntary Saccharin Intake
Figure 2B depicts the result of Ebs (12.5 or 25 mg/kg)
administration on saccharin consumption. The 1-way ANO-
VA demonstrated that this compound did not modify sac-
charin ingestion, F(2, 39) = 1.522, p > 0.05, under these
experimental conditions.
Experiment 5a and 5b: Determination of Brain Catalase
Activity
Figure 3 shows the effect of the combined treatments with
LA (0 or 50 mg/kg; Fig. 3A) or Ebs (0 or 25 mg/kg; Fig. 3B)
and cyanamide (0 or 40 mg/kg) on brain catalase activity.
In Experiment 5a (Fig. 3A), a 2-way ANOVA LA treatment
(0 or 50 mg/kg) 9 cyanamide treatment (0 or 40 mg/kg)
yielded a significant effect for the cyanamide treatment, F(1,
20) = 10.30, p < 0.01, and a significant interaction between
factors, F(1, 20) = 7.11, p < 0.05. Post hoc tests indicated
that the brain catalase activity of mice treated with Vh and
cyanamide (Vh-Cyanamide 40 mg/kg group) was signifi-
cantly lower than that of animals injected with Vh and Sal
(Vh-Cyanamide 0 mg/kg group) (p < 0.01). In contrast, LA
protected catalase against cyanamide inhibition because the
central catalase activity of mice treated with LA (50 mg/kg)
and cyanamide (40 mg/kg) (LA-Cyanamide 40 mg/kg
group) was not altered when this group was compared with
the Vh-Cyanamide 0 mg/kg group (p > 0.05). Moreover, the
brain catalase activity of the LA-Cyanamide 40 mg/kg group
was significantly higher than that of the Vh-Cyanamide 40
group (p < 0.05).
A
B
Fig. 1. Effect of different doses of alpha-lipoic acid (LA) on ethanol
(EtOH) (A) and saccharin (B) intake for 90 minutes. Animals were offered
EtOH (10%; A) and saccharin (0.1%; B) 15 minutes after LA (0, 12.5, 25,
or 50 mg/kg) administration following the described drinking-in-the-dark
procedure (see Materials and Methods section). Bars depict mean ! SEM
of total EtOH (g/kg; A) and saccharin (ml; B) consumption (*p < 0.05 sig-
nificantly different from LA 0 control group).
A
B
Fig. 2. Effect of different doses of ebselen (Ebs) on ethanol (EtOH) (A)
and saccharin (B) intake for 180 minutes. Animals were offered EtOH
(10%; A) and saccharin (0.1%; B) 60 minutes after Ebs (0, 6.25, 12.5, or
25 mg/kg) administration following the described drinking-in-the-dark pro-
cedure (see Materials and Methods section). Bars depict mean ! SEM of
total EtOH (g/kg;A) and saccharin (ml;B) consumption (**p < 0.01 signifi-
cantly different from Ebs 0 control group).
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Similarly, in Fig. 3B, we can observe that Ebs (25 mg/kg)
impeded the impairment of brain catalase mediated by cyan-
amide (40 mg/kg) injection. This conclusion was reported by
a 2-way ANOVA Ebs treatment (0 or 25 mg/kg) 9 cyana-
mide treatment (0 or 40 mg/kg), which found a significant
effect for the cyanamide treatment, F(1, 20) = 5.52, p < 0.05,
and a significant interaction between the 2 factors, F(1,
20) = 10.97, p < 0.01. Again, Duncan’s post hoc testing
revealed that the brain catalase activity of mice treated with
Vh and cyanamide (Vh-Cyanamide 40 mg/kg group) was
significantly lower than that of animals injected with Vh and
Sal (Vh-Cyanamide 0 mg/kg group) (p < 0.01). In contrast,
as occurred with LA, Ebs (25 mg/kg) treatment blocked the
catalase impairment induced by cyanamide administration,
because catalase activity in the brains of mice treated with
Ebs (25 mg/kg) and cyanamide (40 mg/kg) (Ebs-Cyanamide
40 mg/kg group) was not altered when this group was com-
pared with the Vh-Cyanamide 0 mg/kg group (p > 0.05). In
addition, post hoc comparisons demonstrated that catalase
activity was significantly higher in the Ebs-Cyanamide
40 mg/kg group with regard to the Vh-Cyanamide 40 mg/kg
group, thus suggesting that Ebs protects catalase against
cyanamide inhibition (p < 0.01).
DISCUSSION
In the present study, a systemic injection of LA and Ebs
diminished voluntary EtOH intake in mice. Furthermore,
these compounds did not modify saccharin ingestion, at least
at the times and doses tested in our experiments. In addition,
we have found that these treatments were able to reduce
brain H2O2 levels, as measured by the H2O2-dependent inac-
tivation of endogenous brain catalase activity following an
injection of cyanamide. Therefore, we suggest that a reduc-
tion in central H2O2 levels could alter the motivational prop-
erties of EtOH that lead to alcohol binge drinking.
In the DID experiments, LA and Ebs administration dose-
dependently decreased voluntary EtOH consumption. Mice
treated with LA (25 or 50 mg/kg) or Ebs (12.5 or 25 mg/kg)
displayed a significant reduction in their voluntary EtOH
intake. The DID method represents a model of animal EtOH
binge drinking that could be used to explore the mechanisms
underlying high rates of alcohol drinking and to screen new
compounds capable of limiting its excessive intake (Kamdar
et al., 2007; Rhodes et al., 2005). This behavioral procedure
captures important features of alcoholism, such as drinking
to the point of intoxication and rapid initiation to high levels
of drinking (Rhodes et al., 2005). In our experiments, DID
EtOH intakes were consistent with the available literature
demonstrating that the DID model consistently yields high
EtOH consumption over a relatively short time period
(Kamdar et al., 2007; Rhodes et al., 2005). Considering that
binge drinking is a substantial risk factor predicting the
development of alcohol use disorders (Crabbe et al., 2011),
our data are significantly relevant as they represent a valida-
tion of 2 new pharmacological tools to impair EtOH binge
drinking.
Both LA and Ebs are H2O2 scavengers that are able to
decrease the production and the concentrations of reactive
oxygen species (ROS) in the CNS, including H2O2. LA is an
essential cofactor for mitochondrial enzymes that has been
described as a novel biological antioxidant and a potent free
radical scavenger (Somani et al., 2000). This agent partici-
pates in the recycling of vitamins C and E, increases levels of
glutathione, and suppresses nonenzymatic glycation (Suzuki
et al., 1992). Acute administration of LA enhances glutathi-
one peroxidase activity in different regions of the rat brain
and decreases the concentration of ROS, especially H2O2
(Bilska et al., 2007). Similarly, Ebs is a seleno–organic com-
pound with radical-scavenging activity (M€uller et al., 1984).
This compound has been shown to be involved in a number
of antioxidant activities both in vitro and in vivo (Moretto
et al., 2004). Ebs is able to increase the rate of elimination of
H2O2 because it catalyzes the thiol- peroxidase reaction in a
A
B
Fig. 3. Effect of alpha-lipoic acid (LA) (A) and ebselen (Ebs; B) treat-
ment on the inhibition of brain catalase activity induced by cyanamide. Bars
depict mean ! SEM of brain catalase activity (mmol H2O2 degraded/min/
mg protein) (n = 6 per group). LA (0 or 50 mg/kg; A) and Ebs (0 or 25 mg/
kg; B) were administered simultaneously with cyanamide (0 or 40 mg/kg)
treatment and 4 hours later catalase activity was analyzed (**p < 0.01 sig-
nificantly different from its respective Vh-Sal control group; ##p < 0.01,
#p < 0.05 significantly different from its Vh-Cyanamide 40 group). H2O2,
hydrogen peroxide, Vh, vehicle, Sal, saline.
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mechanism that appears to be kinetically identical to the
mechanism of glutathione peroxidase (Parnham and Sies,
2000). In the second set of experiments, we focused on the
effect of LA and Ebs treatment on the inhibitory effect that
sodium cyanamide causes in brain catalase. Cyanamide is a
suicide inhibitor of the enzyme catalase (DeMaster et al.,
1986; Sanchis-Segura et al., 1999). Interestingly, this drug
only inhibits catalase activity when this enzyme reacts to
H2O2 by forming Compound I (Cederbaum and Dicker,
1985; DeMaster et al., 1986).Therefore, the effect of cyana-
mide on catalase activity may be used as an indirect measure
of the capacity of this enzyme to form Compound I, because
the cyanamide-mediated inactivation of brain catalase is
H2O2-dependent. Thus, based on the suggestion that both
LA and Ebs are capable of reducing endogenous H2O2 in
rodents, in Experiments 5a and 5b, we hypothesized that the
inhibition of cerebral catalase induced by cyanamide will be
decreased in mice treated with these compounds. In agree-
ment with this idea, our results showed that brain homogen-
ates of mice treated with LA (50 mg/kg)-Cyanamide (40 mg/
kg) and Ebs (25 mg/kg)-Cyanamide (40 mg/kg) have a
higher catalase activity than Vh-Cyanamide (40 mg/kg)-trea-
ted mice. This indicates that, by reducing H2O2 availability
in the CNS, both LA and Ebs treatments could reduce the
formation of Compound I in the brain. These findings are in
agreement with previous data obtained in our laboratory in
which it has been also showed that both LA and Ebs reduced
the amount of H2O2 available for brain catalase, as measured
by the H2O2-dependent inactivation of central catalase activ-
ity following an injection of AT (Ledesma and Aragon,
2012, 2013; Ledesma et al., 2012).
As outlined above, we propose that both LA and Ebs
reduce the formation of Compound I by decreasing H2O2
levels. As a result, when animals are exposed to EtOH, the
rate of brain-EtOH metabolism would be decreased, thus
preventing voluntary EtOH drinking. As noted earlier, the
first product coming from brain-EtOH metabolism by the
activity of Compound I is acetaldehyde. Acetaldehyde is a
psychoactive molecule that, when administered centrally,
exerts a broad range of behavioral (Arizzi-LaFrance et al.,
2006; Rodd-Henricks et al., 2002; Smith et al., 1984) and
neurochemical (Diana et al., 2008; Enrico et al., 2009; Fod-
dai et al., 2004; Sirca et al., 2011) effects that are similar to
those induced by EtOH in rodents. For this reason, it has
been proposed that brain-EtOH-derived acetaldehyde could
play a role in some of the psychopharmacological effects
caused by EtOH. In agreement to this, it has been observed
that administration of acetaldehyde chelating agents, such as
D-penicillamine and L-cysteine, prevents a wide range of
EtOH-elicited behaviors, including EtOH intake (Font et al.,
2005, 2006; Mart!ı-Prats et al., 2010; Pautassi et al., 2010; Pe-
ana et al., 2010). The results obtained in this study indicated
that H2O2 levels are critical to EtOH intake. We suggest that
in addition to the levels of catalase present in the organisms,
another factor that modulates EtOH-induced behaviors
might be the availability of H2O2, which would determine
the rate of acetaldehyde production at the time of EtOH
administration.
It has been suggested that the mesocorticolimbic dopa-
mine (Da) is involved in EtOH drinking. Various reports
have demonstrated that manipulations that reduce the activ-
ity of this neurotransmitter system decrease voluntary EtOH
intake in rodents (Nguyen et al., 2007; Thanos et al., 2005).
Moreover, acetaldehyde has been shown to be capable of
stimulating the transmission of mesolimbic Da (Deehan
et al., 2013; Deng and Deitrich, 2008; Enrico et al., 2009;
Foddai et al., 2004; Sirca et al., 2011). Several authors have
proposed that acetaldehyde mediates the EtOH-induced
stimulation of mesolimbic Da transmission. It has been
reported that both acetaldehyde sequestration with D-
penicillamine and L-cysteine, or the inhibition of brain
catalase activity by AT prevent the activation of this brain
circuitry evoked by EtOH (Deng and Deitrich, 2008; Enrico
et al., 2009; Sirca et al., 2011). Brain catalase has been
shown to be highly active in aminergic neurons and along
the mesolimbic DA pathway (Deng and Deitrich, 2008;
Zimatkin and Lindros, 1996). Therefore, given the above
studies, we suggest that the reduction in EtOH self-adminis-
tration observed in our experiments could be due to a
decreased activation of this neurotransmitter in the mesolim-
bic DA pathway system.
Alternative explanations should also be considered. That
is, this reduction in volitional EtOH consumption could be
interpreted as being produced by an unspecific alteration of
these pharmacological tools in sensitivity to taste, or an
impairment of some brain areas or neurotransmitter circuitry
related to reinforcement and motivation. However, here, we
showed that voluntary saccharin intake was not affected by
these treatments. Therefore, if the reduction in EtOH drink-
ing was only the result of a general alteration of these
compounds in motivated behavior, we should expect these
drugs to have similar consequences on saccharin ingestion.
Our results demonstrated that these treatments selectively
affected EtOH consumption because saccharin intake
remained unaltered after LA and Ebs administration, thus
ruling out that possibility. As support to this notion, previ-
ous data also showed that the effects of these compounds are
specifically selective for other EtOH-induced behaviors
(Ledesma and Aragon, 2012, 2013; Ledesma et al., 2012).
Another possibility that should be contemplated is that
the capacity of these H2O2 scavengers to diminish volitional
EtOH drinking might be mediated by a modulation in spon-
taneous locomotion or in blood EtOH levels after its admin-
istration. Nonetheless, data obtained in other studies
demonstrated that these compounds did not modify the
baseline motor activity or blood EtOH concentrations in
mice (Ledesma and Aragon, 2012, 2013; Ledesma et al.,
2012).
In conclusion, we propose here a reduction in the activity
of the catalase-H2O2 system as the main mechanism respon-
sible for the interaction between LA and Ebs in modulating
voluntary EtOH self-administration. The current findings
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represent an extension of previous research in which it has
also been suggested that modifications of H2O2 levels in the
CNS could alter some EtOH-induced behaviors (Ledesma
and Aragon, 2012, 2013; Ledesma et al., 2012; Manrique
et al., 2006; Pastor et al., 2002). What is most important here
is that the brain peroxidative status of the organism could
modulate the acute psychopharmacological effects of EtOH.
It seems that variations in the physiological conditions, that
is, in the levels of H2O2 present in the CNS in a particular
moment in the same organism, could determine some effects
induced by EtOH. These data are particularly relevant to
be able to understand the mechanisms underlying the
causes of EtOH binge drinking. Because EtOH binge drink-
ing is a feature of alcoholism, further research is needed to
test the implication of the catalase-H2O2 system in the
EtOH-dependent brain, for example, by performing the
same experiments described here in EtOH-dependent rats.
This should open up the way to the development of new
pharmacological tools to reduce chronic alcohol use.
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